A Study of BL-M08D1 in Patients With Relapsed or Refractory Lymphoid Malignancies

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 2, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions

Relapsed or Refractory Lymphoid Malignancies

Interventions

DRUG

BL-M08D1

Administration by intravenous infusion for a cycle of 3 weeks.

Trial Locations (1)

RECRUITING

Harbin Medical University Cancer Hospital, Harbin

All Listed Sponsors

collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY